TY - JOUR
T1 - Longitudinal MRI atrophy biomarkers
T2 - Relationship to conversion in the ADNI cohort
AU - Risacher, Shannon L.
AU - Shen, Li
AU - West, John D.
AU - Kim, Sungeun
AU - McDonald, Brenna C.
AU - Beckett, Laurel A.
AU - Harvey, Danielle J.
AU - Jack, Clifford R.
AU - Weiner, Michael W.
AU - Saykin, Andrew J.
N1 - Funding Information:
Data analysis was supported in part by the following grants from the National Institutes of Health : NIA R01 AG19771 to AJS and P30 AG10133-18S1 to B. Ghetti and AJS, and NIBIB R03 EB008674 to LS; and by the Indiana Economic Development Corporation ( IEDC # 87884 to AJS).
PY - 2010/8
Y1 - 2010/8
N2 - Atrophic changes in early Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) have been proposed as biomarkers for detection and monitoring. We analyzed magnetic resonance imaging (MRI) atrophy rate from baseline to 1 year in 4 groups of participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI): AD (n = 152), converters from MCI to probable AD (MCI-C, n = 60), stable MCI (MCI-S, n = 261), and healthy controls (HC, n = 200). Scans were analyzed using multiple methods, including voxel-based morphometry (VBM), regions of interest (ROIs), and automated parcellation, permitting comparison of annual percent change (APC) in neurodegeneration markers. Effect sizes and the sample required to detect 25% reduction in atrophy rates were calculated. The influence of APOE genotype on APC was also evaluated. AD patients and converters from MCI to probable AD demonstrated high atrophy APCs across regions compared with minimal change in healthy controls. Stable MCI subjects showed intermediate atrophy rates. APOE genotype was associated with APC in key regions. In sum, APC rates are influenced by APOE genotype, imminent MCI to AD conversion, and AD-related neurodegeneration.
AB - Atrophic changes in early Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) have been proposed as biomarkers for detection and monitoring. We analyzed magnetic resonance imaging (MRI) atrophy rate from baseline to 1 year in 4 groups of participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI): AD (n = 152), converters from MCI to probable AD (MCI-C, n = 60), stable MCI (MCI-S, n = 261), and healthy controls (HC, n = 200). Scans were analyzed using multiple methods, including voxel-based morphometry (VBM), regions of interest (ROIs), and automated parcellation, permitting comparison of annual percent change (APC) in neurodegeneration markers. Effect sizes and the sample required to detect 25% reduction in atrophy rates were calculated. The influence of APOE genotype on APC was also evaluated. AD patients and converters from MCI to probable AD demonstrated high atrophy APCs across regions compared with minimal change in healthy controls. Stable MCI subjects showed intermediate atrophy rates. APOE genotype was associated with APC in key regions. In sum, APC rates are influenced by APOE genotype, imminent MCI to AD conversion, and AD-related neurodegeneration.
KW - Alzheimer's Disease Neuroimaging Initiative (ADNI)
KW - Apolipoprotein E (APOE) epsilon 4 allele
KW - Genetic factors
KW - Hippocampus
KW - Longitudinal change
KW - Magnetic resonance imaging (MRI)
KW - Mild cognitive impairment (MCI)
KW - Voxel-based morphometry (VBM)
UR - http://www.scopus.com/inward/record.url?scp=77953998854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953998854&partnerID=8YFLogxK
U2 - 10.1016/j.neurobiolaging.2010.04.029
DO - 10.1016/j.neurobiolaging.2010.04.029
M3 - Article
C2 - 20620664
AN - SCOPUS:77953998854
VL - 31
SP - 1401
EP - 1418
JO - Neurobiology of Aging
JF - Neurobiology of Aging
SN - 0197-4580
IS - 8
ER -